- Home
- KLRS vs ELUT Comparison
KLRS vs ELUT Comparison
Compare KLRS & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | ELUT |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 45.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLRS | ELUT |
|---|---|---|
| Price | $5.32 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $20.67 | $6.00 |
| AVG Volume (30 Days) | 52.1K | ★ 154.3K |
| Earning Date | 03-17-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | $1.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.14 | $0.50 |
| 52 Week High | $11.88 | $2.99 |
Technical Indicators
Market Signals| Indicator | KLRS | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 22.41 | 48.02 |
| Support Level | $5.10 | $0.86 |
| Resistance Level | $5.38 | $1.16 |
| Average True Range (ATR) | 0.71 | 0.09 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 0.42 | 21.54 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.